Literature DB >> 17482725

Evaluation of combinatorial vaccines against anthrax and plague in a murine model.

Amanda B DuBois1, Lucy C Freytag, John D Clements.   

Abstract

In this study, we examine the potential of a combinatorial vaccine consisting of the lead-candidate antigens for the next generations of vaccines against anthrax (rPA) and plague (F1-V) with the specific objective of determining synergy or interference between the vaccine components when they are administered separately or together by both traditional parenteral immunization (SC) and mucosal immunization (IN) in the presence of appropriate adjuvants. The most significant findings of the study reported here are that (1) a combinatorial vaccine consisting of equal amounts of F1-V and rPA administered SC is effective at eliciting a robust serum and bronchoalveolar lavage (BAL) antigen-specific IgG and IgG1 response against both antigens in immunized animals, and when administered IN, a robust antigen-specific IgG2a response in the serum and BAL is also induced; (2) there were few instances where either synergy or interference was observed in the combined vaccine administered by either route and those differences occurred soon after the final immunization and were not sustained over time; (3) IN immunization was as effective as SC immunization for induction of antigen-specific serum and BAL antibody responses using the same amount of antigen; (4) the IgG1/IgG2a ratios suggest a strongly biased Type 2 response following SC immunization, while IN immunization produced a more balanced Type 1/Type 2 response; (5) the IgG1/IgG2a ratio was influenced by the route of immunization, the adjuvant employed, and the nature of the antigen. As with previously published studies, there were still detectable levels of circulating anti-F1-V and anti-rPA even 6 months post-primary immunization. These studies provide important insights into the development of new generation biodefense vaccines.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17482725      PMCID: PMC1929014          DOI: 10.1016/j.vaccine.2007.03.048

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  43 in total

1.  A dominant-negative therapy for anthrax.

Authors:  S H Leppla
Journal:  Nat Med       Date:  2001-06       Impact factor: 53.440

2.  Risk of vaccine failure after Haemophilus influenzae type b (Hib) combination vaccines with acellular pertussis.

Authors:  J McVernon; N Andrews; M P E Slack; M E Ramsay
Journal:  Lancet       Date:  2003-05-03       Impact factor: 79.321

3.  Effect of nasal immunization with protective antigen of Bacillus anthracis on protective immune response against anthrax toxin.

Authors:  Reetika Gaur; Pradeep K Gupta; Akhil C Banerjea; Yogendra Singh
Journal:  Vaccine       Date:  2002-06-21       Impact factor: 3.641

4.  Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques.

Authors:  I M Belyakov; Z Hel; B Kelsall; V A Kuznetsov; J D Ahlers; J Nacsa; D I Watkins; T M Allen; A Sette; J Altman; R Woodward; P D Markham; J D Clements; G Franchini; W Strober; J A Berzofsky
Journal:  Nat Med       Date:  2001-12       Impact factor: 53.440

5.  The role of antibodies to Bacillus anthracis and anthrax toxin components in inhibiting the early stages of infection by anthrax spores.

Authors:  S Welkos; S Little; A Friedlander; D Fritz; P Fellows
Journal:  Microbiology       Date:  2001-06       Impact factor: 2.777

Review 6.  Vaccination against bubonic and pneumonic plague.

Authors:  R W Titball; E D Williamson
Journal:  Vaccine       Date:  2001-07-20       Impact factor: 3.641

Review 7.  Anthrax.

Authors:  M Mock; A Fouet
Journal:  Annu Rev Microbiol       Date:  2001       Impact factor: 15.500

8.  Mucosal or parenteral administration of microsphere-associated Bacillus anthracis protective antigen protects against anthrax infection in mice.

Authors:  Helen C Flick-Smith; Jim E Eyles; Richard Hebdon; Emma L Waters; Richard J Beedham; Tony J Stagg; Julie Miller; H Oya Alpar; Les W J Baillie; E Diane Williamson
Journal:  Infect Immun       Date:  2002-04       Impact factor: 3.441

9.  Protective immunity and antibody-secreting cell responses elicited by combined oral attenuated Wa human rotavirus and intranasal Wa 2/6-VLPs with mutant Escherichia coli heat-labile toxin in gnotobiotic pigs.

Authors:  L Yuan; C Iosef; M S Azevedo; Y Kim; Y Qian; A Geyer; T V Nguyen; K O Chang; L J Saif
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

10.  B cell responses in gastric antrum and duodenum following oral inactivated Helicobacter pylori whole cell (HWC) vaccine and LT(R192G) in H pylori seronegative individuals.

Authors:  Genevieve A Losonsky; Karen L Kotloff; Richard I Walker
Journal:  Vaccine       Date:  2003-01-17       Impact factor: 3.641

View more
  8 in total

1.  Deletion of Braun lipoprotein and plasminogen-activating protease-encoding genes attenuates Yersinia pestis in mouse models of bubonic and pneumonic plague.

Authors:  Christina J van Lier; Jian Sha; Michelle L Kirtley; Anthony Cao; Bethany L Tiner; Tatiana E Erova; Yingzi Cong; Elena V Kozlova; Vsevolod L Popov; Wallace B Baze; Ashok K Chopra
Journal:  Infect Immun       Date:  2014-03-31       Impact factor: 3.441

2.  A Burkholderia pseudomallei outer membrane vesicle vaccine provides protection against lethal sepsis.

Authors:  Wildaliz Nieves; Hailey Petersen; Barbara M Judy; Carla A Blumentritt; Kasi Russell-Lodrigue; Chad J Roy; Alfredo G Torres; Lisa A Morici
Journal:  Clin Vaccine Immunol       Date:  2014-03-26

3.  Characterization of a mutant Escherichia coli heat-labile toxin, LT(R192G/L211A), as a safe and effective oral adjuvant.

Authors:  Elizabeth B Norton; Louise B Lawson; Lucy C Freytag; John D Clements
Journal:  Clin Vaccine Immunol       Date:  2011-02-02

4.  Immunospecific responses to bacterial elongation factor Tu during Burkholderia infection and immunization.

Authors:  Wildaliz Nieves; Julie Heang; Saja Asakrah; Kerstin Höner zu Bentrup; Chad J Roy; Lisa A Morici
Journal:  PLoS One       Date:  2010-12-17       Impact factor: 3.240

5.  A live attenuated Salmonella Enteritidis secreting detoxified heat labile toxin enhances mucosal immunity and confers protection against wild-type challenge in chickens.

Authors:  Jonathan Lalsiamthara; Nitin Machindra Kamble; John Hwa Lee
Journal:  Vet Res       Date:  2016-06-04       Impact factor: 3.683

6.  Single vector platform vaccine protects against lethal respiratory challenge with Tier 1 select agents of anthrax, plague, and tularemia.

Authors:  Qingmei Jia; Richard Bowen; Barbara Jane Dillon; Saša Masleša-Galić; Brennan T Chang; Austin C Kaidi; Marcus A Horwitz
Journal:  Sci Rep       Date:  2018-05-03       Impact factor: 4.379

7.  Prophylactic administration of bacterially derived immunomodulators improves the outcome of influenza virus infection in a murine model.

Authors:  Elizabeth B Norton; John D Clements; Thomas G Voss; Lucia Cárdenas-Freytag
Journal:  J Virol       Date:  2010-01-06       Impact factor: 5.103

Review 8.  The Mucosal Vaccine Adjuvant LT(R192G/L211A) or dmLT.

Authors:  John D Clements; Elizabeth B Norton
Journal:  mSphere       Date:  2018-07-25       Impact factor: 4.389

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.